Transaction DateRecipientSharesTypePriceValue
16th March 2020Carl Goldfischer690,232Conversion of derivative$0.00
16th March 2020Carl Goldfischer13,148Conversion of derivative$0.00
10th October 2019Sujal Shah5,000Open or private purchase$4.30$21,500.00
23rd September 2019Sujal Shah3,100Open or private purchase$5.55$17,205.00
20th September 2019Sujal Shah1,900Open or private purchase$5.50$10,450.00
7th February 2019Carl Goldfischer2,335Exercise of derivative$5.00$11,675.00
7th February 2019Carl Goldfischer9,340Exercise of derivative$5.50$51,370.00
7th February 2019Carl Goldfischer11,675Open or private sale$9.02$105,328.35
Cyma Bay Therapeutics
Cyma Bay Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company. Its products include MBX-8025 and Arhalofenate. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Ticker: CBAY
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1042074
Employees: 43
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $96 M (286%)
Assets, Current: $174 M (-14%)
Property, Plant and Equipment, Net: $2 M (-13%)
Other Assets, Noncurrent: $160 Th (0%)
Assets: $177 M (-14%)
Accounts Payable, Current: $476 Th (-80%)
Liabilities, Current: $9 M (-46%)
Liabilities: $11 M (-43%)
Common Stock, Value, Issued: $7 Th (0%)
Common Stock, Shares, Issued: $69 M (0%)
Retained Earnings (Accumulated Deficit): $650 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $186 Th (132%)
Stockholders' Equity (Parent): $166 M (0%)
Liabilities and Equity: $177 M (-14%)
Research and Development: $8 M (-54%)
General and Administrative Expenses: $3 M (-56%)
Restructuring Charges: $188 Th (60%)
Operating Income/Loss: $11 M (-55%)
Other Income, net: $426 Th (-66%)
EPS (basic): $0.16 (0%)
EPS (diluted): $0.16 (0%)